Capricor Therapeutics CFO Anthony Bergmann Buys Company Shares
Anthony Bergmann, CFO of Capricor Therapeutics, purchased shares of the company on June 24, 2026.
Key Points
- Anthony Bergmann, CFO of Capricor Therapeutics, bought 400 shares at $3.18 each on June 24, 2026.
- Capricor Therapeutics, listed on NasdaqGS as CAPR, has a market cap of about $1.7 billion and a 52-week high of $40.37.
- Analysts like B. Riley Securities and Piper Sandler have maintained a 'buy' rating on Capricor, with price targets ranging up to $63.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Anthony Bergmann, the Chief Financial Officer of Capricor Therapeutics, Inc. (NasdaqGS: CAPR), purchased 400 shares of the company on June 24, 2026. The shares were acquired at an average price of $3.18 each, totaling approximately $1,272.
Insider Buying and Selling at Capricor Therapeutics, Inc.
On June 24, 2026, Anthony Bergmann, the CFO, bought 400 shares at $3.18, not under a pre-planned trading program. Additionally, Karen Krasney, EVP and General Counsel, made multiple transactions on the same day, purchasing 400 shares at $3.18 and selling 400 shares at $30.00.
Capricor Therapeutics, Inc. Stock Up 207.7%
Shares of Capricor Therapeutics traded near $29.60 on Thursday. The company, which is listed on the NasdaqGS under the ticker CAPR, has a market capitalization of about $1.7 billion. Capricor's stock has fluctuated between a 52-week low of $4.30 and a high of $40.37. The company's forward P/E ratio is not meaningful as it isn't profitable, and it has a beta of 0.368, indicating lower volatility compared to the market.
$CAPR stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Several analysts have reiterated their positive outlook on Capricor Therapeutics. On March 13, 2026, B. Riley Securities maintained a 'buy' rating with a price target of $63. Piper Sandler also reiterated a 'buy' rating, setting a target of $58. HC Wainwright & Co. maintained their 'buy' rating with a $60 target on March 10, 2026. The consensus among analysts is a 'strong buy,' with an average target price of $54.11 based on nine analyst opinions.
About Capricor Therapeutics
Capricor Therapeutics, Inc. is a biotechnology company based in San Diego, California. The company focuses on developing cell and exosome-based therapeutics for diseases with unmet medical needs, such as Duchenne muscular dystrophy. Their lead product candidate, Deramiocel, is in Phase 3 clinical trials. Capricor also works on an exosome-based vaccine for COVID-19, along with other therapeutic applications.
Bottom Line
Capricor Therapeutics remains a company of interest, particularly with insider buying activity from its CFO. While the stock has experienced significant price movement, analysts continue to view it positively. Investors should note that insider transactions and analyst ratings often provide insights but are not definitive indicators of future performance.
Get Capricor Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $CAPR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.